Cambridge-based cell therapy firm Vericel Corp. has forged a $142 million deal to license a gel used to help heal burns that made just over $3 million in sales last year at an Israeli company.
Vericel (Nasdaq: VCEL) will pay $17.5 million upfront and up to $125 million in milestones to license and sell the burn repair product NexoBrid from Israeli company MediWound Ltd., it announced Tuesday. The gel uses enzymes to remove burned tissue, with around 93 percent of subjects experiencing complete removal…
